Federal Register Proposed rule and direct final rule: FDA is proposing to amend the biologics regulations by removing, revising, or updating specific regulations applicable to blood, blood components, and source plasma to be more consistent with current practices in the blood industry and to remove unnecessary or outdated requirements. To view this proposed rule, click here.
